Evaxion announces business update and second quarter 2026 financial results
Evaxion reported a Q2 net loss of $3.7 million, narrowing from $4.8 million in the year-ago quarter, with cash and equivalents of $14.0 million funding operations into the second half of 2027. Pipeline progress includes upcoming three-year data for EVX-01 in melanoma at ESMO 2026, new data for EVX-04 in AML, and the expansion of its off-the-shelf pipeline with EVX-05 for glioblastoma.
Key figures
- Revenue
- 0
- Net loss
- 3729000
- Ga expenses
- 1512000
- Rd expenses
- 2334000
- Cash and equivalents
- 14000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.